World Journal of *Clinical Cases*

World J Clin Cases 2020 December 26; 8(24): 6213-6545





Published by Baishideng Publishing Group Inc

W J C C World Journal of Clinical Cases

Contents

Semimonthly Volume 8 Number 24 December 26, 2020

MINIREVIEWS

6213 Role of gut microbiome in regulating the effectiveness of metformin in reducing colorectal cancer in type 2 diabetes

Huang QY, Yao F, Zhou CR, Huang XY, Wang Q, Long H, Wu QM

ORIGINAL ARTICLE

Retrospective Cohort Study

6229 Impact factors of lymph node retrieval on survival in locally advanced rectal cancer with neoadjuvant therapy

Mei SW, Liu Z, Wang Z, Pei W, Wei FZ, Chen JN, Wang ZJ, Shen HY, Li J, Zhao FQ, Wang XS, Liu Q

Retrospective Study

- Three-year follow-up of Coats disease treated with conbercept and 532-nm laser photocoagulation 6243 Jiang L, Qin B, Luo XL, Cao H, Deng TM, Yang MM, Meng T, Yang HQ
- 6252 Virus load and virus shedding of SARS-CoV-2 and their impact on patient outcomes Chen PF, Yu XX, Liu YP, Ren D, Shen M, Huang BS, Gao JL, Huang ZY, Wu M, Wang WY, Chen L, Shi X, Wang ZQ, Liu YX, Liu L, Liu Y
- 6264 Risk factors for de novo hepatitis B during solid cancer treatment

Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T

6274 Cause analysis and reoperation effect of failure and recurrence after epiblepharon correction in children Wang Y, Zhang Y, Tian N

Clinical Trials Study

6282 Effects of different acupuncture methods combined with routine rehabilitation on gait of stroke patients Lou YT, Yang JJ, Ma YF, Zhen XC

Observational Study

- 6296 Application of endoscopic submucosal dissection in duodenal space-occupying lesions Li XY, Ji KY, Qu YH, Zheng JJ, Guo YJ, Zhang CP, Zhang KP
- 6306 Early renal injury indicators can help evaluate renal injury in patients with chronic hepatitis B with longterm nucleos(t)ide therapy Ji TT, Tan N, Lu HY, Xu XY, Yu YY



Contents

Semimonthly Volume 8 Number 24 December 26, 2020

Prospective Study

6315 Neoadjuvant chemoradiotherapy plus surgery in the treatment of potentially resectable thoracic esophageal squamous cell carcinoma

Yan MH, Hou XB, Cai BN, Qu BL, Dai XK, Liu F

CASE REPORT

- 6322 Uterine rupture in patients with a history of multiple curettages: Two case reports Deng MF, Zhang XD, Zhang QF, Liu J
- 6330 Pleural effusion and ascites in extrarenal lymphangiectasia caused by post-biopsy hematoma: A case report

Lin QZ, Wang HE, Wei D, Bao YF, Li H, Wang T

6337 Eighty-year-old man with rare chronic neutrophilic leukemia caused by CSF3R T618I mutation: A case report and review of literature

Li YP, Chen N, Ye XM, Xia YS

- 6346 Sigmoid colon duplication with ectopic immature renal tissue in an adult: A case report Namgung H
- 6353 Paraplegia from spinal intramedullary tuberculosis: A case report Qu LM, Wu D, Guo L, Yu JL
- 6358 Confocal laser endomicroscopy distinguishing benign and malignant gallbladder polyps during choledochoscopic gallbladder-preserving polypectomy: A case report

Tang BF, Dang T, Wang QH, Chang ZH, Han WJ

6364 Sclerosing stromal tumor of the ovary with masculinization, Meig's syndrome and CA125 elevation in an adolescent girl: A case report

Chen Q, Chen YH, Tang HY, Shen YM, Tan X

- 6373 Primary pulmonary malignant melanoma diagnosed with percutaneous biopsy tissue: A case report Xi JM, Wen H, Yan XB, Huang J
- 6380 SRY-negative 45,X/46,XY adult male with complete masculinization and infertility: A case report and review of literature

Wu YH, Sun KN, Bao H, Chen YJ

6389 Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report

Komeda Y, Sakurai T, Sakai K, Morita Y, Hashimoto A, Nagai T, Hagiwara S, Matsumura I, Nishio K, Kudo M

6396 Immunotherapies application in active stage of systemic lupus erythematosus in pregnancy: A case report and review of literature

Xiong ZH, Cao XS, Guan HL, Zheng HL



	World Journal of Clinical Cases				
Conter	nts Semimonthly Volume 8 Number 24 December 26, 2020				
6408	Minimally invasive maxillary sinus augmentation with simultaneous implantation on an elderly patient: A case report				
	Yang S, Yu W, Zhang J, Zhou Z, Meng F, Wang J, Shi R, Zhou YM, Zhao J				
6418	Congenital nephrogenic diabetes insipidus due to the mutation in <i>AVPR2</i> (c.541C>T) in a neonate: A case report				
	Lin FT, Li J, Xu BL, Yang XX, Wang F				
6425	Primary gastric melanoma in a young woman: A case report Long GJ, Ou WT, Lin L, Zhou CJ				
6432	Extreme venous letting and cupping resulting in life-threatening anemia and acute myocardial infarction: A case report				
	Jang AY, Suh SY				
6437	Novel conservative treatment for peritoneal dialysis-related hydrothorax: Two case reports				
	Dai BB, Lin BD, Yang LY, Wan JX, Pan YB				
6444	Clinical characteristics of pulmonary cryptococcosis coexisting with lung adenocarcinoma: Three case reports				
	Zheng GX, Tang HJ, Huang ZP, Pan HL, Wei HY, Bai J				
6450	Fracture of the scapular neck combined with rotator cuff tear: A case report				
	Chen L, Liu CL, Wu P				
6456	Synchronous colonic mucosa-associated lymphoid tissue lymphoma found after surgery for adenocarcinoma: A case report and review of literature				
	Li JJ, Chen BC, Dong J, Chen Y, Chen YW				
6465	Novel mutation in the <i>ASXL3</i> gene in a Chinese boy with microcephaly and speech impairment: A case report				
	Li JR, Huang Z, Lu Y, Ji QY, Jiang MY, Yang F				
6473	Recurrent thrombosis in the lower extremities after thrombectomy in a patient with polycythemia vera: A case report				
	Jiang BP, Cheng GB, Hu Q, Wu JW, Li XY, Liao S, Wu SY, Lu W				
6480	Status epilepticus as an initial manifestation of hepatic encephalopathy: A case report <i>Cui B, Wei L, Sun LY, Qu W, Zeng ZG, Liu Y, Zhu ZJ</i>				
6487	Delayed diagnosis of prosopagnosia following a hemorrhagic stroke in an elderly man: A case report				
	Yuan Y, Huang F, Gao ZH, Cai WC, Xiao JX, Yang YE, Zhu PL				
6499	Oral myiasis after cerebral infarction in an elderly male patient from southern China: A case report				
	Zhang TZ, Jiang Y, Luo XT, Ling R, Wang JW				
6504	Rare case of drain-site hernia after laparoscopic surgery and a novel strategy of prevention: A case report <i>Gao X, Chen Q, Wang C, Yu YY, Yang L, Zhou ZG</i>				
	Guo 2, Chon Q, Hung C, 1u 11, 1ung D, Lhou DO				



Conter	<i>World Journal of Clinical Cases</i> Semimonthly Volume 8 Number 24 December 26, 2020
6511	Extracorporeal shock wave therapy treatment of painful hematoma in the calf: A case report <i>Jung JW, Kim HS, Yang JH, Lee KH, Park SB</i>
6517	Takotsubo cardiomyopathy associated with bronchoscopic operation: A case report <i>Wu BF, Shi JR, Zheng LR</i>
6524	Idiopathic adulthood ductopenia with elevated transaminase only: A case report Zhang XC, Wang D, Li X, Hu YL, Wang C
6529	Successful endovascular treatment with long-term antibiotic therapy for infectious pseudoaneurysm due to <i>Klebsiella pneumoniae</i> : A case report <i>Wang TH, Zhao JC, Huang B, Wang JR, Yuan D</i>
6537	Primary duodenal tuberculosis misdiagnosed as tumor by imaging examination: A case report Zhang Y, Shi XJ, Zhang XC, Zhao XJ, Li JX, Wang LH, Xie CE, Liu YY, Wang YL



Contents

Semimonthly Volume 8 Number 24 December 26, 2020

ABOUT COVER

Peer-Reviewer of World Journal of Clinical Cases, Dr. Adonis Protopapas is a gastroenterology Resident at the first Propaedeutic Department of Internal Medicine of the Aristotle University of Thessaloniki (Greece), located at the A.H.E.P.A Hospital. He earned his Bachelor's degree in 2015 from the Democritus University of Thrace, followed by three Master's of Science degrees, with specializations in clinic pharmacology, medical research methodology, and healthcare management. His research interests are mainly focused on the area of hepatology, although he also participates in various projects related to endoscopy and inflammatory bowel disease. He is particularly fascinated by research on cirrhosis and its complications. (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for WJCC as 1.013; IF without journal self cites: 0.991; Ranking: 120 among 165 journals in medicine, general and internal; and Quartile category: Q3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Ji-Hong Liu; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Clinical Cases	https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 2307-8960 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
April 16, 2013	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Semimonthly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Dennis A Bloomfield, Sandro Vento, Bao-gan Peng	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/2307-8960/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
December 26, 2020	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2020 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2020 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



W J C C World Journal of Clinical Cases

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2020 December 26; 8(24): 6229-6242

DOI: 10.12998/wjcc.v8.i24.6229

ISSN 2307-8960 (online)

ORIGINAL ARTICLE

Retrospective Cohort Study Impact factors of lymph node retrieval on survival in locally advanced rectal cancer with neoadjuvant therapy

Shi-Wen Mei, Zheng Liu, Zheng Wang, Wei Pei, Fang-Ze Wei, Jia-Nan Chen, Zhi-Jie Wang, Hai-Yu Shen, Juan Li, Fu-Qiang Zhao, Xi-Shan Wang, Qian Liu

ORCID number: Shi-Wen Mei 0000-0002-9735-3261; Zheng Liu 0000-0002-8831-0761; Zheng Wang 0000-0002-9021-7160; Wei Pei 0000-0001-5201-6432; Fang-Ze Wei 0000-0001-8955-447X; Jia-Nan Chen 0000-0002-6673-6884; Zhi-Jie Wang 0000-0003-2930-4668; Hai-Yu Shen 0000-0002-2961-5098; Juan Li 0000-0002-1839-7857; Fu-Qiang Zhao 0000-0003-0676-8371; Xi-Shan Wang 0000-0002-1675-5083; Qian Liu 0000-0003-2510-3113.

Author contributions: Mei SW,

Chen JN and Wang ZJ designed the research; Wei FZ, Shen HY, Li J and Zhao FQ collected the data; Pei W, Wang Z, Liu Z and Wei FZ analyzed the data; Mei SW drafted the manuscript; Liu Q and Wang XS revised the paper.

Supported by National Key Research and Development Plan "Research on Prevention and Control of Major Chronic Non-Communicable Diseases", No. 2019YFC1315705; and The Medicine and Health Technology Innovation Project of Chinese Academy of Medical Sciences, No. 2017-12M-1-006.

Institutional review board

statement: The study received approval from the ethics

Shi-Wen Mei, Zheng Liu, Zheng Wang, Wei Pei, Fang-Ze Wei, Jia-Nan Chen, Zhi-Jie Wang, Hai-Yu Shen, Juan Li, Fu-Qiang Zhao, Xi-Shan Wang, Qian Liu, Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Corresponding author: Qian Liu, MD, Chief Doctor, Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. fcwpumch@163.com

Abstract

BACKGROUND

Conventional clinical guidelines recommend that at least 12 lymph nodes should be removed during radical rectal cancer surgery to achieve accurate staging. The current application of neoadjuvant therapy has changed the number of lymph node dissection.

AIM

To investigate factors affecting the number of lymph nodes dissected after neoadjuvant chemoradiotherapy in locally advanced rectal cancer and to evaluate the relationship of the total number of retrieved lymph nodes (TLN) with diseasefree survival (DFS) and overall survival (OS).

METHODS

A total of 231 patients with locally advanced rectal cancer from 2015 to 2017 were included in this study. According to the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) classification system and the NCCN guidelines for rectal cancer, the patients were divided into two groups: group A (TLN \ge 12, *n* = 177) and group B (TLN < 12, n = 54). Factors influencing lymph node retrieval were analyzed by univariate and binary logistic regression analysis. DFS and OS were evaluated by Kaplan-Meier curves and Cox regression models.

RESULTS

The median number of lymph nodes dissected was 18 (range, 12-45) in group A



committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Approval No. 17-116/1439).

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors declare there is no conflict of interest in regard to this research.

Data sharing statement: No additional data are available.

STROBE statement: The authors have read the STROBE Statementchecklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: htt p://creativecommons.org/License s/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Specialty type: Medicine, research and experimental

Country/Territory of origin: China

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B Grade C (Good): 0 Grade D (Fair): 0 Grade E (Poor): 0

Received: August 23, 2020 Peer-review started: August 23,

and 8 (range, 2-11) in group B. The lymph node ratio (number of positive lymph nodes/total number of lymph nodes) (P = 0.039) and the interval between neoadjuvant therapy and radical surgery (P = 0.002) were independent factors of the TLN. However, TLN was not associated with sex, age, ASA score, clinical T or N stage, pathological T stage, tumor response grade (Dworak), downstaging, pathological complete response, radiotherapy dose, preoperative concurrent chemotherapy regimen, tumor distance from anal verge, multivisceral resection, preoperative carcinoembryonic antigen level, perineural invasion, intravascular tumor embolus or degree of differentiation. The pathological T stage (P < 0.001) and TLN (P < 0.001) were independent factors of DFS, and pathological T stage (P= 0.011) and perineural invasion (P = 0.002) were independent factors of OS. In addition, the risk of distant recurrence was greater for TLN < 12 (P = 0.009).

CONCLUSION

A shorter interval to surgery after neoadjuvant chemoradiotherapy for rectal cancer under indications may cause increased number of lymph nodes harvested. Tumor shrinkage and more extensive lymph node retrieval may lead to a more favorable prognosis.

Key Words: Lymph node retrieval; Survival analysis; Neoadjuvant therapy; Rectal cancer; Tumor-node-metastasis stage; Prognosis

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The number of lymph node retrieval and survival on surgery after neoadjuvant therapy in rectal cancer are still under debate. This study analyzes the effects of lymph node retrieval in rectal cancer after neoadjuvant therapy on patient survival. We concluded that a shorter interval to surgery after neoadjuvant chemoradiotherapy for rectal cancer under indications caused increased number of lymph nodes harvested. Tumor shrinkage and more extensive lymph node retrieval may lead to a more favorable prognosis.

Citation: Mei SW, Liu Z, Wang Z, Pei W, Wei FZ, Chen JN, Wang ZJ, Shen HY, Li J, Zhao FQ, Wang XS, Liu Q. Impact factors of lymph node retrieval on survival in locally advanced rectal cancer with neoadjuvant therapy. World J Clin Cases 2020; 8(24): 6229-6242 URL: https://www.wjgnet.com/2307-8960/full/v8/i24/6229.htm DOI: https://dx.doi.org/10.12998/wjcc.v8.i24.6229

INTRODUCTION

The internationally recognized tumor-node-metastasis (TNM) classification system is widely practiced in the staging of clinical malignant tumors. Since first proposed by a Frenchman, Pierre Denoix, between 1943 and 1952, the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) have gradually established international classification standards, and in 1968, the first edition of the TNM classification of malignant tumors was published^[1,2]. Currently, 8 editions of the TNM classification system for colorectal cancer have been developed, and the 8th edition has become a widely used reference for colorectal oncologists globally^[3]. With social and economic development, colorectal cancer now ranks third in the world in terms of morbidity and mortality^[4]. In China, colorectal cancer is also a serious threat to human health. Locally advanced rectal cancer accounts for the majority of colorectal cancer cases. Positive lymph nodes (pN1-2) suggest a risk of systemic metastasis and unfavorable prognosis^[5]. The harvest of fewer than 12 lymph nodes has been identified as a predictor of unfavorable outcomes in rectal cancer according to the National Comprehensive Cancer Network (NCCN) guidelines, and this cut-off is regarded as a standard in surgical treatment^[6,7]. With the widespread application of neoadjuvant therapy for rectal cancer, in general, the number of lymph nodes harvested is negatively correlated with tumor regression. The total number of retrieved lymph nodes (TLN) is often less than 12 after neoadjuvant therapy, which has a debatable



2020

First decision: October 18, 2020 Revised: October 20, 2020 Accepted: November 4, 2020 Article in press: November 4, 2020 Published online: December 26, 2020

P-Reviewer: Protopapas A S-Editor: Gao CC L-Editor: MedE-Ma JY P-Editor: Liu JH



effect on the rate of local recurrence and distant metastasis^[8,9]. The lymph node ratio (LNR) is also a prognostic factor that is inversely correlated with survival outcomes^[8,10,11]. Furthermore, accurate pathological staging plays an important role in determining the postoperative treatment regimen for rectal cancer, and more extensive lymph node retrieval can reduce local recurrence. There have been no large clinical trials investigating whether neoadjuvant chemoradiotherapy affects the TLN.

Various factors influencing lymph node retrieval during surgery make it difficult to determine the influence on the node stage (pN)^[12]. Weight, sex, pelvic structure, specimen length and surgical procedure type are factors that may influence the retrieval of lymph nodes^[13,14]. Interestingly, a lower N stage can be the result of lymph nodes not being sufficiently dissected by the surgeon or some of the lymph nodes being missed by the pathologist during specimen collection. This phenomenon is due to the neoadjuvant therapy which reduces the size of the tumor and the number of positive lymph nodes^[15].

Anatomically, the circumferential margin of involvement of tumors in the rectum is similar to that of tumors in the colon invading the mesocolon, but the rectum is quite different from the colon in terms of the lymph node distribution. This difference leads to a higher recurrence rate of locally advanced rectal cancer (cN+). Therefore, preoperative neoadjuvant therapy plus radical total mesorectal excision (TME) as the standard therapy regimen has been applied in locally advanced rectal cancer^[16]. Logically, fewer lymph nodes may be retrieved due to neoadjuvant chemoradiotherapy, and the TLN can thus be influenced by the chemotherapy regimen, radiotherapy dose and tumor response to chemoradiotherapy. A larger TLN may suggest a poorer prognosis.

In the present study, we examined the TLN as an indication for the most suitable neoadjuvant and surgical treatment regimen.

MATERIALS AND METHODS

Patients

We analyzed the data of 231 patients who were clinically diagnosed with locally advanced rectal cancer. All patients were admitted to the Colorectal Surgery Department of the National Cancer Center/National Sciences Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, between November 2014 and August 2017 and enrolled in the treatment regimen, which was preoperative neoadjuvant therapy followed by laparoscopic TME^[17]. The cohort was divided into two groups, with 12 lymph nodes as the boundary and the TLN determined by surgeons and pathologists. We investigated the factors that may affect the TLN, as well as factors associated with prognosis, including clinical characteristics, clinical T and N stage, pathological T and N stage, preoperative chemotherapy regimen, radiotherapy dose, TLN, LNR, surgical procedure, pathological outcomes and follow-up data (Table 1). This research was approved by the ethics committee of our institution, and informed consent to collect clinical data was obtained from each patient following the principles of the World Medical Association Declaration of Helsinki. We excluded patients who were diagnosed with clinical TNM stage I and IV disease, other carcinomas or lesions, obstruction, perforation, or bleeding, who were treated with palliative resection and who refused to accept chemoradiotherapy.

Neoadjuvant therapy

According to the AICC/UICC 8th edition TNM classification system^[18], patients with stage II and III disease were treated with neoadjuvant chemoradiotherapy. The preoperative radiotherapy dose typically ranged from 45 Gy-50.4 Gy and was administered according to a long-course regimen; some patients were treated with a short-course radiotherapy regimen with a total dose of 25 Gy. Radiation was delivered to the pelvic cavity and tumor bed at an energy of 10 MV. The following chemotherapy regimens were administered concurrently with radiation: XELOX; oral capecitabine alone; and other regimens of fluorouracil combined with other agents.

Pathological analysis

All surgical specimens were sent for examination and fixation with paraffin in a timely manner after surgery. The pathologists were blinded to the patient information during analysis of the specimens. The final pathological TNM stage was classified using the AJCC/UICC 8th edition classification system. Our institution also uses the tumor



Table 1 Patient characteristics			
Variable	TLN ≥ 12 (group A, <i>n</i> = 177)	TLN < 12 (group B, <i>n</i> = 54)	<i>P</i> value
Sex (n, %)			0.591
Male	121 (68.4)	39 (72.2)	
Female	56 (31.6)	15 (27.8)	
Age (yr)	60 (51-65)	59.5 (52.75-66.5)	0.544
ASA score (<i>n</i> , %)			0.488
1	5 (2.8)	2 (3.7)	
2	139 (78.6)	39 (72.2)	
3	33 (18.6)	13 (24.1)	
BMI (kg/m ²)	23.8 (21.9-26.4)	23.4 (21.5-25.2)	0.423
cT, n (%)			0.975
2	2 (1.1)	0 (0)	
3	137 (77.4)	43 (79.6)	
4	38 (21.5)	11 (20.4)	
cN, n (%)			0.109
0	44 (24.9)	18 (33.3)	
1	91 (51.4)	28 (51.9)	
2	42 (23.7)	8 (14.8)	
Preoperative CEA (µg/L)	2.99 (1.55-5.57)	3 (1.68-5.57)	0.729
ypT, n (%)			0.140
0	26 (14.7)	14 (25.9)	
1	4 (2.3)	1 (1.9)	
2	37 (20.9)	11 (20.4)	
3	97 (54.8)	24 (44.4)	
4	13 (7.3)	4 (7.4)	
ypN, <i>n</i> (%)			0.026
0	90 (50.8)	38 (70.4)	
1	64 (36.2)	10 (18.5)	
2	23 (13)	6 (11.1)	
TRG, n (%)			0.312
0	14 (7.9)	4 (7.4)	
1	26 (14.7)	7 (13)	
2	78 (44.1)	22 (40.7)	
3	33 (18.6)	7 (13)	
4	26 (14.7)	14 (25.9)	
No downstaging, <i>n</i> (%)	98 (55.4)	20 (37)	0.019
Downstaging, n (%)	56 (31.6)	21 (38.9)	0.324
pCR, <i>n</i> (%)	26 (14.7)	14 (25.9)	0.057
Positive lymph nodes, <i>n</i> (%)	0 (0-1)	0 (0-0)	0.003
LNR	0 (0-0.68)	0 (0-0)	0.012
Radiotherapy dose, n (%)			0.557
45-50.4 Gy/28 F	125 (70.6)	39 (72.2)	



< 45 Gy/25 F	34 (19.2)	5 (9.3)	
25 Gy/5 F	18 (10.2)	10 (18.5)	
Preoperative concurrent chemotherapy regimen, n (%)			0.376
Capecitabine+ oxaliplatin	54 (30.5)	17 (31.5)	
Capecitabine, oral	108 (61)	37 (68.5)	
Fluorouracil union	15 (8.5)	0 (0)	
Tumor location, DAV (cm)	5 (3-7)	5 (3-7)	0.605
Interval, w (%)	8 (6.5-11)	10 (8-16)	0.001
Surgical procedure			0.018
Miles (<i>n</i> , %)	74 (41.8)	26 (48.2)	
Dixon (<i>n</i> , %)	93 (52.5)	20 (37)	
Hartmann (n, %)	10 (5.6)	8 (14.8)	
LLND (<i>n</i> , %)	20 (11.3)	1 (1.9)	0.035
Multivisceral resection $(n, \%)$	10 (5.6)	2 (3.7)	0.574
PNI (<i>n</i> , %)			0.819
Yes	42 (23.7)	12 (22.2)	
No	135 (76.3)	42 (77.8)	
Intravascular tumor embolus (<i>n</i> , %)			0.463
Yes	23 (13)	5 (9.3)	
No	154 (87)	49 (90.7)	
Degree of differentiation, <i>n</i> (%)			0.367
Low and low-middle grades	18 (10.2)	9 (16.7)	
Middle, high-middle, and high grades	132 (74.6)	43 (79.6)	
Signet-ring and mucinous adenocarcinoma	4 (2.3)	2 (3.7)	

TLN: Total number of retrieved lymph nodes; BMI: Body mass index; CEA: Carcinoembryonic antigen; ASA: American Society of Anesthesiologists; TRG: Tumor regression grade; LNR: Lymph node ratio; DAV: Distance from anal verge; LLND: Lateral lymph node dissection; PNI: Perineural invasion; pCR: Pathological complete response; F: Fractions.

regression grade (TRG, Dworak), ranging from 0 to 4: TRG0, the tumor tissue showed no significant regression macro- or microscopically; TRG1, the tumor tissue showed < 25% shrinkage microscopically; TRG2, the tumor tissue showed 25%-50% shrinkage microscopically; TRG3, the tumor tissue showed > 50% shrinkage microscopically; and TRG4, no residual tumor cells were observed microscopically. Perineural invasion (PNI) was defined as tumor cells invading any layer of the nerve sheath or tumor cells growing along the nerve wrapping more than 1/3 of the nerve circumference, and intravascular tumor embolus was defined by tumor cell invasion of the lymphatic vessels or vessels of the intestinal wall.

Follow-up

Follow-up was conducted in the outpatient clinic or by telephone or email. Clinical and chest, abdominal and pelvic enhanced computed tomography examinations were performed to detect recurrence. Patients were followed up every three months postoperatively for the first two years. If there was no recurrence after two years, patients were followed up every six months once a year. Colonoscopy was performed every six months during the first two years and once a year after the first two years. Disease-free survival (DFS) was analyzed from the day of surgery to the date of tumor-related recurrence. Overall survival (OS) was defined as the time between the date of surgery and cancer-related death. The last date to follow-up was March 22, 2020. The median follow-up was 41 mo.

Beishideng® WJCC | https://www.wjgnet.com

Statistical analysis

The first part of our statistical analysis focused on factors affecting the TLN. Patient characteristics were analyzed with univariate and binary logistic regression analyses. On univariate analysis, we compared categorical variables with the Chi-squared test or Fisher's exact test, and continuous variables that did not conform to the normal distribution were calculated by Mann-Whitney U test and were displayed as the median (range). Variables with P values less than 0.05 on univariate analysis were included in the binary logistic regression analysis.

The second part of the analysis examined whether DFS and OS were correlated with the TLN. Factors influencing the prognosis were analyzed by the Kaplan-Meier method and then included in Cox proportional hazards regression models with the aim of determining independent factors affecting DFS and OS.

All statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS) version 26.0 for Mac (IBM Corp, NY, United States).

RESULTS

Table 1 shows the clinicopathological features of the patients. There was no significant difference between the two groups except the operating time interval and the lymph node ratio, as shown in Table 2 by binary regression analysis. The median follow-up period was 41 mo (range, 2-62), with no difference between the groups. Fourteen (7.9%) patients in group A and 7 (13%) patients in group B experienced local recurrence (P = 0.259). The total number of deaths in the cohort was 27 (15.3%) in group A and 9 (16.7%) in group B (P = 0.803). Although there was no significant difference between the two groups, the local recurrence rate and death rate were higher in group B (TLN < 12) than in group A (TLN \ge 12). More patients in group B than in group A experienced distant recurrence (group A, 19.8% vs group B, 37%, P = 0.009). Table 3 presents the tumor-related outcomes in both groups.

At the same time, the above potential prognostic factors were analyzed as categorical variables by the Kaplan-Meier method. The cumulative DFS rate, which was determined by the date of tumor recurrence, was higher in group A (TLN \ge 12) than in group B (TLN < 12) (group A, 68.9% vs group, B 40%, P = 0.006), but there was no difference between the groups in OS (group A, 79% vs group B, 81%, P = 0.737) (Figure 1). Other factors leading to a significant difference in DFS included clinical N stage (P = 0.003), pathological T stage (P < 0.001) and N stage (P < 0.001), positive lymph nodes (P < 0.001), LNR (P < 0.001), interval (P = 0.044), multivisceral resection (P = 0.025), PNI (P < 0.001), intravascular tumor embolus (P < 0.001), and degree of differentiation (P = 0.028), and factors causing a significant difference in OS included pathological T stage (P < 0.001), PNI (P < 0.001), and intravascular tumor embolus (P =0.004). All factors affecting survival were incorporated into the Cox proportional hazards regression model for further analysis. Table 4 presents the survival outcomes in both groups. We found that the TLN [P < 0.001, odds ratio (OR): 0.302, 95% confidence interval (CI): 0.172-0.531] and pathological T stage (P < 0.001) were independent predictors of DFS, while PNI (P = 0.002, OR: 3.74, 95% CI: 1.634-8.529) and pathological T stage (P = 0.002) were independent predictors of OS, as shown in Table 5.

DISCUSSION

Comprehensive treatment regimens are constantly updated. Currently, the accepted standard treatment scheme is preoperative neoadjuvant chemoradiotherapy followed by radical surgery, but improvements in treatment are made with the ultimate aim of improving the long-term survival rate and quality of life of patients. The TNM classification system in the AJCC cancer staging manual (8th edition, 2017) is used as the current staging standard for rectal cancer; the TNM stage is not only the most important prognostic predictor in rectal cancer but also critical to the selection of a postoperative treatment regimen. There are few factors affecting the evaluation of the T and M stage, but the N stage is established based on the number of lymph nodes harvested, and both the TLN and number of positive lymph nodes are influenced by the surgical and pathological techniques^[19]. In our study, the interval between neoadjuvant therapy and surgery was an independent factor of the number of lymph nodes harvested. This outcome is similar to that of a study performed by Sermier



Table 2 Binary regression analysis				
	<i>P</i> value	OR	95%CI	
No downstaging	0.640	0.797	0.309-2.061	
Positive lymph nodes	0.152	0.873	0.725-1.051	
ypN0 vs ypN2	0.059	8.239	0.92-73.794	
ypN1 vs ypN2	0.442	2.228	0.289-17.163	
LNR	0.039	66.666	1.239-3587.217	
Interval	0.002	1.084	1.029-1.142	
LLND	0.086	0.165	0.021-1.287	

LNR: Lymph node ratio; LLND: Lateral lymph node dissection; OR: Odds ratio; CI: Confidence interval.

Table 3 Oncologic outcomes					
Variable	TLN ≥ 12 (group A, <i>n</i> = 177)	TLN < 12 (group B, <i>n</i> = 54)	P value		
Local recurrence, <i>n</i> (%)	14 (7.9)	7 (13)	0.259		
Distant recurrence, n (%)	35 (19.8)	20 (37)	0.009		
Death, <i>n</i> (%)	27 (15.3)	9 (16.7)	0.803		

TLN: Total number of retrieved lymph nodes

et al^[20]; they found that the TLN in abdominoperineal resection was impacted by the interval between neoadjuvant therapy and surgery and the administration of neoadjuvant radiotherapy. Neoadjuvant therapy not only controlled the local recurrence rate after surgery but also reduced the TLN. There are various factors affecting the detection of lymph nodes in rectal cancer after neoadjuvant therapy. Prolonging the interval after neoadjuvant therapy can improve the local pathological response rate^[21-23], and neoadjuvant therapy may play a paramount role in treating tumors over time. However, there seems to be a contradiction, as neoadjuvant therapy can also reduce the lymph node retrieval rate and the accuracy of TNM staging. Some studies have indicated that fewer lymph nodes are detected during surgery after neoadjuvant therapy^[22,24-26]. Farinella *et al*^[22] concluded that small lymph nodes (≤ 5 mm) impacted the N stage. We found that small lymph nodes (≤ 5 mm) accounted for 76.5% of lymph nodes retrieved in our study, which increased the difficulty in accurately identifying the N stage due to atrophy, fibrosis and even necrosis. In a total of 5647 patients who were enrolled in an analysis of the Surveillance, Epidemiology and End Results (SEER) database in 2005, the number of lymph nodes retrieved and the N stage were affected by the administration of neoadjuvant therapy^[27]. We analyzed whether neoadjuvant chemoradiotherapy combined with chemoradiotherapy had a sensitization effect on radiotherapy. Theoretically, compared with preoperative radiotherapy, preoperative chemoradiotherapy should significantly reduce the TLN. In this regard, it has also been reported that preoperative chemoradiotherapy has more advantages in terms of tumor shrinkage and tumor persistence than preoperative radiotherapy alone^[28].

The effect of the minimum number of harvested lymph nodes on rectal cancer has been discussed between surgeons and pathologists. The effect of the number of lymph nodes harvested in rectal cancer on survival is also a controversial issue. With increasing lymph node dissection and detection, the stage determined according to the TNM classification system becomes increasingly accurate. Considering the effect of neoadjuvant therapy on the accuracy of the N stage, the LNR has been used as a prognostic indicator in some studies^[29,30]. Ceelen et al^[31] performed a systematic review and analysis of a total of 33 984 patients and found that the prognostic value of positive lymph nodes was inferior to that of the LNR. There was another interesting study on the prognostic value of the number of lymph nodes. Sun et al[32] reported that the number of negative lymph nodes for ypN+ after neoadjuvant therapy was a prognostic factor for DFS (number of negative lymph nodes \geq 17, hazard ratio = 0.400,



Variable No. of cases DFS P value OS P value Sex $(n, \%)$ 0.708 0.655 Male 160 (69.3) $$
Male 160 (69.3) Female 71 (30.7) Age (yr) 0.86 < 60
Female 71 (30.7) Age (yr) 0.86 0.968 < 60
Age (yr) 0.86 0.968 < 60
< 60 111 (48.1) ≥ 60 120 (51.9) ASA score (n, %) 0.912 0.951
≥ 60 120 (51.9) ASA score (n, %) 0.912 0.951
ASA score (n, %) 0.912 0.951
1 7 (2)
1 7 (3)
2 178 (77)
3 46 (19.9)
BMI (kg/m ²) 0.519 0.512
< 25 149 (64.5)
≥ 25 82 (35.5)
cT, n (%) 0.606 0.476
2 2 (0.9)
3 180 (77.9)
4 49 (21.2)
cN, n (%) 0.003 0.063
0 79 (34.2)
1 112 (48.5)
2 40 (17.3)
ypT, n (%) < 0.001 < 0.001
0 36 (15.6)
1 6 (2.6)
2 50 (21.6)
3 122 (52.8)
4 17 (7.4)
ypN, n (%) < 0.001 0.097
0 128 (55.4)
1 74 (32)
2 29 (12.6)
TLN, n (%) 0.006 0.737
< 12 54 (23.4)
≥12 177 (76.6)
Positive lymph nodes, n (%) < 0.001 0.063
< 2 182 (78.8)
≥ 2 49 (21.2)
LNR < 0.001 0.058
≤ 0.03
> 0.03
Preoperative concurrent chemotherapy regimen, n (%) 0.148 0.561

Capecitabine+ oxaliplatin	58 (25.1)		
Capecitabine, oral	140 (60.6)		
Oxaliplatin combination	22 (9.5)		
Postoperative chemotherapy		0.933	0.869
Yes	153 (66.2)		
No	78 (33.8)		
Interval, w (%)		0.044	0.567
$\leq 8 \text{ wk}$	139 (60.2)		
> 8 wk	92 (39.8)		
Surgical procedure		0.168	0.662
Miles (<i>n</i> , %)	100 (43.3)		
Dixon (<i>n</i> , %)	113 (48.9)		
Hartmann (n, %)	18 (7.8)		
LLND (<i>n</i> , %)	21 (9.1)	0.868	0.994
Multivisceral resection $(n, \%)$	12 (5.2)	0.025	0.948
Preoperative CEA (µg/L)		0.344	0.663
<5	166 (71.9)		
≥5	65 (28.1)		
PNI (n, %)		< 0.001	< 0.001
Yes	54 (23.4)		
No	177 (76.6)		
Intravascular tumor embolus (<i>n</i> , %)		< 0.001	0.004
Yes	28 (12.1)		
No	203 (87.9)		
Degree of differentiation, n (%)		0.028	0.152
Low and low-middle grades	32 (13.9)		
Middle, high-middle, and high grades	193 (83.5)		
Signet-ring and mucinous adenocarcinoma	6 (2.6)		

DFS: Disease-free survival; OS: Overall survival; BMI: Body mass index; ASA: American Society of Anesthesiologists; LLND: Lateral lymph node dissection; TLN: Total number of retrieved lymph nodes; CEA: Carcinoembryonic antigen; PNI: Perineural invasion.

> P = 0.022). Persiani *et al*^[33] conducted a study involving 345 patients treated with neoadjuvant therapy followed by surgery, and they indicated that more lymph nodes were retrieved in cases of a less extensive tumor response and a shorter interval between neoadjuvant therapy and surgery. Hall et al^[34] indicated that the TLN was strongly correlated with OS, with a cut-off value of 8 lymph nodes. Onitilo $et al^{[35]}$, in a retrospective cohort study of 708 patients with rectal cancer treated over the past 10 years, divided the 708 patients into the surgery alone group (279, SURG) and the neoadjuvant therapy plus surgery group (479, NEO) for comparison; the TLN showed a significant difference between the two groups (NEO 10.8 vs SURG 15.5, P < 0.001). In contrast, the disease-specific survival in the SURG group was not superior to that in the NEO group. The conclusion of this study explained that neoadjuvant therapy may eliminate the potential positive lymph nodes, leading to a decrease in the retrieval of lymph nodes after radical surgery, and that neoadjuvant therapy plays a concurrent role in controlling local recurrence. In our study, even with neoadjuvant therapy followed by radical resection for rectal cancer, TLN < 12 remained unfavorable in terms of DFS. Considering that the number of lymph nodes detected is affected by many factors, it is important to establish an effective system that re-evaluates the true number of positive lymph nodes harvested for accurate staging after neoadjuvant therapy. This is difficult because there is no method to evaluate the true rate of lymph



Table 5 Results of Cox regression analysis of disease-free survival and overall survival

		Disease	Disease-free survival			Overall survival	
	P value	HR	95%CI	P value	HR	95%CI	
cN0 vs cN1	0.620	0.794	0.318-1.978	0.801	0.84	0.217-3.249	
cN0 vs cN2	0.496	1.281	0.628-2.610	0.296	1.712	0.625-4.693	
ypT0 vs ypT4	< 0.001	0.074	0.019-0.288	0.011	0.11	0.02-0.607	
ypT1 vs ypT4	0.338	0.46	0.094-2.253	0.494	0.464	0.051-4.202	
ypT2 vs ypT4	< 0.001	0.097	0.032-0.301	0.002	0.035	0.004-0.305	
ypT3 vs ypT4	0.014	0.418	0.209-0.837	0.011	0.309	0.125-0.761	
ypN0 vs ypN1	0.745	0.823	0.254-2.664	0.805	1.245	0.219-7.086	
ypN0 vs ypN2	0.706	1.178	0.504-2.756	0.816	1.156	0.341-3.92	
TLN ($\geq 12 vs < 12$	< 0.001	0.302	0.172-0.531	0.606	0.8	0.342-1.871	
LNR ($\leq 0.03 \ vs \ 0.03$)	0.840	0.914	0.379-2.20	0.768	1.228	0.314-4.799	
Positive lymph nodes ($\geq 2 vs \leq 2$)	0.828	1.1	0.466-2.593	0.978	0.982	0.271-3.562	
Interval ($\leq 8 \text{ wk } vs > 8 \text{ wk}$)	0.236	1.369	0.814-2.303	0.626	0.836	0.408-1.715	
Multivisceral resection	0.119	1.875	0.851-4.13	0.792	0.816	0.181-3.69	
PNI	0.051	1.8	0.998-3.248	0.002	3.747	1.634-8.592	
Intravascular tumor embolus	0.244	1.479	0.766-2.858	0.584	1.292	0.517-3.23	
Degree of differentiation							
Low and low-middle grades <i>vs</i> signet-ring and mucinous adenocarcinoma	0.695	0.739	0.163-3.354	0.811	0.76	0.08-7.221	
Middle, high-middle, and high grades <i>vs</i> signet-ring and mucinous adenocarcinoma	0.929	0.930	0.19-4.564	0.913	1.141	0.106-12.243	

TLN: Total number of retrieved lymph nodes; LNR: Lymph node ratio; DFS: Disease-free survival; OS: Overall survival; PNI: Perineural invasion; HR: Hazard ratio; CI: Confidence interval.


> node positivity. However, to deal with the issue of inaccurate N staging, two methods can be utilized. First, as more lymph nodes are harvested to be assessed, the accuracy of staging node-positive disease progressively increases^[35-38]; thus, the rate of positive lymph node detection becomes infinitely closer to the true value. Additionally, DFS would seem to improve partly because of shift in staging. Second, a systematic review of many studies can be performed to identify factors affecting DFS on the basis of lymph node dissection. A study of the cohort of patients from the randomized EORTC trial 22921 indicated that DFS was not improved by postoperative adjuvant chemotherapy in patients treated with neoadjuvant chemoradiotherapy^[39]. On the other hand, the EORTC trial suggested that the accuracy rate of N staging after neoadjuvant therapy followed by surgery may need to be improved to better plan for postoperative care.


> Our study has several limitations. The first limitation is its retrospective nature. Second, there may be bias in the information collected, but the cohort showed acceptable homogeneity. A future multicenter, randomized controlled or cohort trial with a larger sample size may be needed to verify factors of lymph node retrieval after neoadjuvant therapy. Third, the radiotherapy dose administered to patients in our cohort varied because of discrepancies in clinical practice.

CONCLUSION

The TLN may help to predict the prognosis in colorectal cancer. Neoadjuvant therapy caused decreased number of lymph nodes detected, leading to inaccurate staging. The retrieval of more lymph nodes may improve the accuracy of TNM staging and result in a more favorable prognosis.







ARTICLE HIGHLIGHTS

Research background

Surgery with total mesorectal excision following neoadjuvant therapy is a standard regime for locally advanced rectal cancer. The number of lymph node retrieval and survival on surgery after neoadjuvant therapy in rectal cancer are still under debate.

Research motivation

There is a lack of consensus concerning the actual number of lymph node retrieval in surgery after neoadjuvant therapy. Whether less or more 12 lymph nodes should be retrieved is controversial. Data are limited regarding outcomes of different number of lymph node retrieval.

Research objectives

The main aim of this study is to investigate whether different number of lymph node retrieval affects the rate of pathological complete response, preoperative outcomes and survival status.

Research methods

This was a retrospective cohort study to collect the data of patients after neoadjuvant therapy for locally advanced rectal cancer. According to the clinicopathological characteristics and other data, the influence of neoadjuvant therapy on the number of lymph node dissection was analyzed.

Raishideng® WJCC | https://www.wjgnet.com

Research results

A shorter interval to surgery after neoadjuvant chemoradiotherapy for rectal cancer under indications may cause increased number of lymph nodes harvested. Tumor shrinkage and more extensive lymph node retrieval may lead to a more favorable prognosis.

Research conclusions

The TLN may help to predict the prognosis in colorectal cancer. Neoadjuvant therapy caused a decrease in the number of lymph nodes detected, leading to inaccurate staging. The retrieval of more lymph nodes may improve the accuracy of TNM staging and result in a more favorable prognosis.

Research perspectives

Prospective randomized trials are required to evaluate the optimal number of lymph node retrieval that is needed to achieve minimum morbidity, and minimum disease recurrence.

REFERENCES

- 1 **Doll R.** The Pierre Denoix Memorial Lecture: nature and nurture in the control of cancer. *Eur J* Cancer 1999; 35: 16-23 [PMID: 10211083 DOI: 10.1016/s0959-8049(98)00348-7]
- Horiuchi J. [TNM classification of UICC (1974). Comparison between the old and new classifications for mouth and tongue neoplasms]. Rinsho Hoshasen 1976; 21: 393-398 [PMID: 9873621
- 3 Loughrey MB, Kent O, Moore M, Coghlin C, Kelly P, McVeigh G, Coleman HG. Impact on colorectal cancer pathology reporting practice of migration from TNM 5 to TNM 8. Histopathology 2020; 77: 210-222 [PMID: 32285464 DOI: 10.1111/his.14116]
- 4 Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-1953 [PMID: 30350310 DOI: 10.1002/ijc.31937]
- 5 Ahmed M. Colon Cancer: A Clinician's Perspective in 2019. Gastroenterology Res 2020; 13: 1-10 [PMID: 32095167 DOI: 10.14740/gr1239]
- Levine RA, Chawla B, Bergeron S, Wasvary H. Multidisciplinary management of colorectal cancer 6 enhances access to multimodal therapy and compliance with National Comprehensive Cancer Network (NCCN) guidelines. Int J Colorectal Dis 2012; 27: 1531-1538 [PMID: 22645076 DOI: 10.1007/s00384-012-1501-z]
- 7 Li Destri G, Di Carlo I, Scilletta R, Scilletta B, Puleo S. Colorectal cancer and lymph nodes: the obsession with the number 12. World J Gastroenterol 2014; 20: 1951-1960 [PMID: 24587671 DOI: 10.3748/wjg.v20.i8.1951]
- Isik A, Peker K, Firat D, Yilmaz B, Sayar I, Idiz O, Cakir C, Demiryilmaz I, Yilmaz I. Importance of 8 metastatic lymph node ratio in non-metastatic, lymph node-invaded colon cancer: a clinical trial. Med Sci Monit 2014; 20: 1369-1375 [PMID: 25087904 DOI: 10.12659/MSM.890804]
- Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JM. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer 2009; 115: 5432-5440 [PMID: 19673001 DOI: 10.1002/cncr.24622]
- 10 Pvo JS, Kim JH, Lee SY, Baek TH, Kang DW. Metastatic Lymph Node Ratio (mLNR) is a Useful Parameter in the Prognosis of Colorectal Cancer; A Meta-Analysis for the Prognostic Role of mLNR. Medicina (Kaunas) 2019; 55: 673 [PMID: 31590275 DOI: 10.3390/medicina55100673]
- 11 Ramos-Esquivel A, Juárez M, González I, Porras J, Rodriguez L. Prognosis impact of the lymph node ratio in patients with colon adenocarcinoma: a single-centre experience. J Gastrointest Cancer 2014; 45: 133-136 [PMID: 24382601 DOI: 10.1007/s12029-013-9576-5]
- 12 He HF, Zhou MQ, Chen JQ, Tian W, Cai HK, Chen LR, Deng YC. Enhanced lymph node retrieval from colorectal cancer resections using a simple lymphatic staining method. Hepatogastroenterology 2012; 59: 375-379 [PMID: 21940392 DOI: 10.5754/hge11319]
- Feng H, Zhao XW, Zhang Z, Han DP, Mao ZH, Lu AG, Thasler WE. Laparoscopic Complete 13 Mesocolic Excision for Stage II/III Left-Sided Colon Cancers: A Prospective Study and Comparison with D3 Lymph Node Dissection. J Laparoendosc Adv Surg Tech A 2016; 26: 606-613 [PMID: 27183112 DOI: 10.1089/lap.2016.0120]
- Thorn CC, Woodcock NP, Scott N, Verbeke C, Scott SB, Ambrose NS. What factors affect lymph 14 node yield in surgery for rectal cancer? Colorectal Dis 2004; 6: 356-361 [PMID: 15335370 DOI: 10.1111/j.1463-1318.2004.00670.x
- Marks JH, Valsdottir EB, Rather AA, Nweze IC, Newman DA, Chernick MR. Fewer than 12 Lymph 15 nodes can be expected in a surgical specimen after high-dose chemoradiation therapy for rectal cancer. Dis Colon Rectum 2010; 53: 1023-1029 [PMID: 20551754 DOI: 10.1007/DCR.0b013e3181dadeb4
- 16 Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L,



Glimelius B, van Krieken JH, Leer JW, van de Velde CJ; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646 [PMID: 11547717 DOI: 10.1056/NEJMoa010580]

- 17 Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-1482 [PMID: 2425199 DOI: 10.1016/s0140-6736(86)91510-2]
- Weiser MR. AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol 2018; 25: 1454-1455 [PMID: 18 29616422 DOI: 10.1245/s10434-018-6462-1]
- 19 Mechera R, Schuster T, Rosenberg R, Speich B. Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: A systematic review and meta-analysis. Eur J Cancer 2017; 72: 84-94 [PMID: 28027520 DOI: 10.1016/j.ejca.2016.10.031]
- Sermier A, Gervaz P, Egger JF, Dao M, Allal AS, Bonet M, Morel P. Lymph node retrieval in 20 abdominoperineal surgical specimen is radiation time-dependent. World J Surg Oncol 2006; 4: 29 [PMID: 16749931 DOI: 10.1186/1477-7819-4-29]
- 21 Dias AR, Pereira MA, de Mello ES, Nahas SC, Cecconello I, Ribeiro U Jr. Lymph Node Yield After Neoadjuvant Chemoradiotherapy in Rectal Cancer Specimens: A Randomized Trial Comparing Two Fixatives. Dis Colon Rectum 2018; 61: 888-896 [PMID: 29944580 DOI: 10.1097/DCR.000000000001097]
- 22 Farinella E, Viganò L, Fava MC, Mineccia M, Bertolino F, Capussotti L. In vivo lymph node mapping and pattern of metastasis spread in locally advanced mid/Low rectal cancer after neoadjuvant chemoradiotherapy. Int J Colorectal Dis 2013; 28: 1523-1529 [PMID: 23877264 DOI: 10.1007/s00384-013-1727-4]
- 23 de Campos-Lobato LF, Stocchi L, de Sousa JB, Buta M, Lavery IC, Fazio VW, Dietz DW, Kalady MF. Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think! Ann Surg Oncol 2013; 20: 3398-3406 [PMID: 23812804 DOI: 10.1245/s10434-013-3010-x]
- Wang BH, Zhang GN, Xiao Y, Wu B, Lin GL, Cui QC, Hu K, Zhong GX, Qiu HZ. [Impact of 24 neoadjuvant therapy on lymph nodes retrieval in locally advanced mid-low rectal carcinoma]. Zhonghua Waike Zazhi 2009; 47: 1779-1783 [PMID: 20193545]
- 25 Zhao YL, Cao DM, Zhou QC, Yang N, Yao HL. Accuracy of Endorectal Endoscopic Ultrasound (EUS) for Locally Advanced Rectal Cancer (LARC) Restaging After Neoadjuvant Chemoradiotherapy (NAT): A Meta-Analysis. Hepatogastroenterology 2014; 61: 978-983 [PMID: 26158152
- Morcos B, Baker B, Al Masri M, Haddad H, Hashem S. Lymph node yield in rectal cancer surgery: 26 effect of preoperative chemoradiotherapy. Eur J Surg Oncol 2010; 36: 345-349 [PMID: 20071133 DOI: 10.1016/j.ejso.2009.12.006]
- 27 Baxter NN, Morris AM, Rothenberger DA, Tepper JE. Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis. Int J Radiat Oncol Biol Phys 2005; 61: 426-431 [PMID: 15667963 DOI: 10.1016/j.ijrobp.2004.06.259]
- 28 Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123 [PMID: 16971718 DOI: 10.1056/NEJMoa060829]
- Manilich EA, Kiran RP, Radivoyevitch T, Lavery I, Fazio VW, Remzi FH. A novel data-driven 29 prognostic model for staging of colorectal cancer. J Am Coll Surg 2011; 213: 579-588, 588.e1-588.e2 [PMID: 21925905 DOI: 10.1016/j.jamcollsurg.2011.08.006]
- Tong LL, Gao P, Wang ZN, Song YX, Xu YY, Sun Z, Xing CZ, Wang X, Xu HM. Can lymph node 30 ratio take the place of pN categories in the UICC/AJCC TNM classification system for colorectal cancer? Ann Surg Oncol 2011; 18: 2453-2460 [PMID: 21455596 DOI: 10.1245/s10434-011-1687-2]
- 31 Ceelen W, Van Nieuwenhove Y, Pattyn P. Prognostic value of the lymph node ratio in stage III colorectal cancer: a systematic review. Ann Surg Oncol 2010; 17: 2847-2855 [PMID: 20559741 DOI: 10.1245/s10434-010-1158-1]
- Sun Y, Zhang Y, Huang Z, Chi P. Prognostic Implication of Negative Lymph Node Count in ypN+ 32 Rectal Cancer after Neoadjuvant Chemoradiotherapy and Construction of a Prediction Nomogram. J Gastrointest Surg 2019; 23: 1006-1014 [PMID: 30187336 DOI: 10.1007/s11605-018-3942-3]
- Persiani R, Biondi A, Gambacorta MA, Bertucci Zoccali M, Vecchio FM, Tufo A, Coco C, Valentini 33 V, Doglietto GB, D'Ugo D. Prognostic implications of the lymph node count after neoadjuvant treatment for rectal cancer. Br J Surg 2014; 101: 133-142 [PMID: 24375303 DOI: 10.1002/bjs.9341]
- 34 Hall MD, Schultheiss TE, Smith DD, Fakih MG, Kim J, Wong JY, Chen YJ. Impact of Total Lymph Node Count on Staging and Survival After Neoadjuvant Chemoradiation Therapy for Rectal Cancer. Ann Surg Oncol 2015; 22 Suppl 3: S580-S587 [PMID: 25956577 DOI: 10.1245/s10434-015-4585-1]
- Onitilo AA, Stankowski RV, Engel JM, Doi SA. Adequate lymph node recovery improves survival in 35 colorectal cancer patients. J Surg Oncol 2013; 107: 828-834 [PMID: 23592545 DOI: 10.1002/jso.23332]
- Moro-Valdezate D, Pla-Martí V, Martín-Arévalo J, Belenguer-Rodrigo J, Aragó-Chofre P, Ruiz-36 Carmona MD, Checa-Ayet F. Factors related to lymph node harvest: does a recovery of more than 12 improve the outcome of colorectal cancer? Colorectal Dis 2013; 15: 1257-1266 [PMID: 24103076 DOI: 10.1111/codi.12424]
- Fan L, Levy M, Aguilar CE, Mertens RB, Dhall D, Frishberg DP, Wang HL. Lymph node retrieval 37 from colorectal resection specimens for adenocarcinoma: is it worth the extra effort to find at least 12



nodes? Colorectal Dis 2011; 13: 1377-1383 [PMID: 20969717 DOI: 10.1111/j.1463-1318.2010.02472.x]

- 38 Govindarajan A, Gönen M, Weiser MR, Shia J, Temple LK, Guillem JG, Paty PB, Nash GM. Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy. J Clin Oncol 2011; 29: 4568-4573 [PMID: 21990400 DOI: 10.1200/JCO.2011.37.2235]
- Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, 39 Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L; EORTC Radiation Oncology Group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014; 15: 184-190 [PMID: 24440473 DOI: 10.1016/S1470-2045(13)70599-0]





Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

